Quantcast
Last updated on April 17, 2014 at 15:50 EDT

Latest Rhinitis Stories

2013-05-14 16:27:36

MISSISSAUGA, ON, May 14, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that the United States Patent Office has granted U.S. Patent # 8,435,568, relating to compositions and methods of using WF10 and new derivative formulations for the treatment of allergic asthma, allergic rhinitis and...

2013-04-23 08:33:51

New Survey Reveals the Impact of Nasal Allergies on Sleep, Relationships and Productivity LANDOVER, Md., April 23, 2013 /PRNewswire/ -- The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory released results today from a new survey which showed that more than half (59 percent) of nasal allergy sufferers polled reported sleep issues as a result of their allergy symptoms, yet only 35 percent proactively treat their nasal allergy symptoms. Furthermore, nearly half of...

2013-04-03 08:27:36

-Indicated for seasonal & perennial allergic rhinitis in children ages 2 and up MONMOUTH JUNCTION, N.J., April 3, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Karbinal(TM) ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine...

2013-03-13 23:01:22

Lifetime Health Australia reminds seasonal allergy sufferers that natural relief may be at hand with Quercetin - a natural antihistamine found in a range of foods and health supplements. Sydney, NSW (PRWEB) March 14, 2013 Quercetin is thought to be a useful natural defense against allergic reactions as it demonstrates both anti-histamine and anti-inflammatory activity. Quercetin is often referred to as a ℠natural antihistamine´ as it is thought to minimize the release of...

2013-01-30 16:25:04

CHICAGO, Jan. 30, 2013 /PRNewswire/ -- Seasonal allergies are somewhat predictable and each year the media is quick to point out pollen count peaks. But how much do you know about your own personal allergen triggers? According to Chicago allergist Dr. Brian Rotskoff of Clarity Allergy Center, you can significantly improve your quality of life by learning about and preparing for your own "high-sneeze, high-itch" months. Not only will your nose feel better, controlling the symptoms of hay fever...

2013-01-01 05:03:23

“Seasonal Allergic Rhinitis — Pipeline Review, H2 2012” & “Coronary Artery Disease (CAD) (Ischemic Heart Disease) — Pipeline Review, H2 2012” are the latest reports added to online market research library of RnRMarketResearch.com Dallas, Texas (PRWEB) January 01, 2013 This report provides information on the therapeutic development for Seasonal Allergic Rhinitis & Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with latest updates,...

2012-12-21 08:23:22

CHICAGO, Dec. 21, 2012 /PRNewswire/ -- December is a time for wrapping up the year and wrapping up the fun. But if you're a chronic headache sufferer, putting on a happy holiday can be tough. Leading Chicago allergy doctor, Brian Rotskoff, MD, helps patients keep holiday headaches under control. It starts, he says, with learning what causes your migraine headaches or sinus headaches and what it takes to cross your headache threshold. Dr. Rostkoff's expertise includes the full range of needs...

2012-12-19 04:20:40

LEIDEN - The Netherlands, December 19, 2012 /PRNewswire/ -- HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC(R) FIX Phleum pratense. This combined dose tolerability and dose range finding study will characterize the dose-response relationship of SUBLIVAC(R) FIX Phleum pratense in order to support the optimal dose in terms of clinical efficacy and safety for further investigation in Phase III studies....

2012-11-06 12:27:00

LEIDEN, Netherlands, November 6, 2012 /PRNewswire/ -- HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC(R) FIX Birch. This combined dose tolerability and dose range finding study will characterize the dose-response relationship of SUBLIVAC(R) FIX Birch in order to support the optimal dose in terms of clinical efficacy and safety. The multi-centre, randomized, double-blind, placebo-controlled study in...

2012-10-18 11:25:52

YARDLEY, Pa., Oct. 18, 2012 /PRNewswire/ -- OptiNose US Inc., today announced the publication of results from a study which showed that the proportion of the dose delivered to the blood vessel-rich middle and upper posterior regions in the back of the nose is three times higher with the OptiNose breath-powered Bi-Directional(TM) nasal delivery device than traditional liquid nasal spray. The study "Nasal Deposition and Clearance in Man: Comparison of a Bi-directional Powder Device and a...